BioXcel Therapeutics, Inc…announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for approval of IGALMI for at-home use in the acute treatment of agitation associated with bipolar disorders or schizophrenia.

Igalmi (dexmedetomedine sublingual) - BioXcel

Apr 1, 2026